Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis

Light chain (AL) amyloidosis is a plasma cell neoplasm associated with insoluble fibril deposition from clonal immunoglobulin chains systemically. The disease is associated with high early mortality and morbidity owing to advanced organ deposition as well as lack of proven de-fibrillogenic therapies...

Full description

Saved in:
Bibliographic Details
Published in:Contemp Clin Trials Commun
Main Authors: D'Souza, Anita, Flynn, Kathryn, Chhabra, Saurabh, Dhakal, Binod, Hamadani, Mehdi, Jacobsen, Kirsten, Pasquini, Marcelo, Weihrauch, Dorothee, Hari, Parameswaran
Format: Artigo
Language:Inglês
Published: Elsevier 2017
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5898504/
https://ncbi.nlm.nih.gov/pubmed/29696194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.conctc.2017.08.012
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items